Calpain-1 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Calpain-1 (CAPN1; UniProt P07384), expressed in HEK293 cells. Suitable for calcium-dependent protease activity assays, inhibitor IC50 determination, substrate cleavage studies, and antibody validation.
Expression system
HEK293
Cat. #
REC-Calpain1

In stock

SKU
REC-Calpain1
$498.00

Target Overview

Calpain-1 (UniProt P07384; gene CAPN1) is the catalytic large subunit of the μ-calpain holoenzyme, a calcium-regulated, non-lysosomal cysteine protease (EC 3.4.22.52) that requires micromolar calcium concentrations for activation. The full-length human sequence spans 714 amino acids and comprises four structural domains: a papain-like cysteine protease domain (domain II), a domain III with C2-domain-like topology, and a penta-EF-hand calcium-binding domain (domain IV) that mediates heterodimerisation with the regulatory small subunit CAPNS1. This recombinant protein is expressed in HEK293 mammalian cells, a system that supports the post-translational folding and disulfide environment appropriate for a protease of this structural complexity, and is supplied in a formulation compatible with direct use in enzymatic assays. Researchers use this recombinant in several experimental contexts. In activity assays, it serves as the enzyme source for measuring cleavage of fluorogenic substrates (e.g., Suc-LLVY-AMC) and natural protein substrates including CTBP1 and caspase-7 (CASP7). In inhibitor screening, the purified enzyme enables concentration-response IC50 determination for calpain inhibitor compounds under defined, cell-free conditions. For antibody validation, this recombinant functions as a positive-control antigen in Western blot and dot-blot formats; researchers pairing this protein with the matched Triple Point Biologics anti-Calpain-1 antibody (SKU: RP-Calpain1) can confirm band identity at the expected molecular weight of the catalytic subunit. The HEK293 expression system also makes this recombinant suitable as a structurally native immunogen for generating or benchmarking binding reagents directed against conformational epitopes.

Background

Calpain-1 (CAPN1) is one of two ubiquitously expressed "conventional" calpain isoforms — alongside calpain-2 — that together constitute the best-characterised members of the mammalian calpain superfamily. As a calcium-activated cysteine protease localised to the cytoplasm, calpain-1 executes limited, non-degradative proteolysis of a defined substrate repertoire, thereby acting as a molecular switch in cytoskeletal remodeling and signal transduction rather than a bulk protein-degradation enzyme. Documented substrates include CTBP1, cleaved at Asn-375, Gly-387, and His-409, and the apoptosis effector CASP7, which calpain-1 processes to an active form — placing it at the intersection of calcium signaling and programmed cell death pathways (UniProt P07384). In the nervous system, calpain-1 and calpain-2 have been investigated for their opposing roles in synaptic plasticity. A published study by Pestereva et al. (2026, PMID: 42322566) examined how dopamine modulates calpain 1 and calpain 2 activity across rat brain regions, reflecting broader research interest in how neuromodulatory signals are transduced through calpain-mediated proteolysis. Calpain-1 has also been studied extensively as a research target in cardiac biology. Shen et al. (2026, PMID: 42102612) reported that exosomal miR-124 derived from M2 macrophages suppresses Calpain-1 expression in a model of hypertensive cardiac remodeling, implicating calpain-1 as a downstream effector in maladaptive cardiac responses. Separately, Ross et al. (2026, PMID: 42018559) demonstrated that inhibition of calpain-mediated HMGB1 processing alleviates cardiac inflammation in a dietary stress model, highlighting the enzyme's role in inflammatory substrate processing. Wang et al. (2026, PMID: 41786157) further linked the calpain regulatory subunit CAPNS1 to NETosis and myocarditis, underscoring how calpain system components operate in immune-mediated cardiac injury. Beyond cardiac contexts, calpain activity has been characterised in the context of proteostasis stress. Sideri et al. (2026, PMID: 41750347) employed comparative proteomics in CHO cell lines under proteasome inhibition, a model system in which endogenous calpain pathway perturbations are routinely monitored. Collectively, these published studies illustrate why a well-characterised, mammalian-expressed recombinant Calpain-1 is a practical reagent for researchers running cell-free enzyme assays, validating inhibitor candidates, or generating quantitative standards for proteomics workflows. This recombinant is research-use only and is not intended for diagnostic or therapeutic applications.

Applications

  • Calcium-dependent protease activity assay using fluorogenic substrates (e.g., Suc-LLVY-AMC or casein-based substrates)
  • Inhibitor IC50 determination in cell-free calpain inhibitor screening assays
  • Substrate identification and cleavage-site mapping by mass spectrometry (e.g., CTBP1, CASP7 cleavage)
  • Western blot positive-control antigen for anti-Calpain-1 antibody validation (pair with TPB SKU: RP-Calpain1)
  • Dot-blot and slot-blot antigen standards for antibody titration and specificity confirmation
  • Enzyme kinetics (Km, Vmax, kcat) characterisation under defined calcium concentration gradients
  • Biophysical binding studies (SPR, ITC) to measure inhibitor or regulatory protein interaction affinities
  • Recombinant substrate preparation for calpain-2 vs. calpain-1 selectivity profiling in comparative protease panels

References

  1. Pestereva N et al. Regulation of calpain 1 and calpain 2 activity by dopamine in rat brain regions. Cell Mol Biol (Noisy-le-grand). 2026. doi:10.14715/cmb/2025.72.2.3. PMID: 42322566.
  2. Shen H et al. Exosomal miR-124 from M2 macrophages protects against hypertensive cardiac remodeling through suppression of Calpain-1. Int Immunopharmacol. 2026. doi:10.1016/j.intimp.2026.116805. PMID: 42102612.
  3. Ross C et al. Inhibition of calpain-mediated HMGB1 alleviates cardiac inflammation and dysfunction induced by ultra-processed foods. JCI Insight. 2026. doi:10.1172/jci.insight.199622. PMID: 42018559.
  4. Wang Y et al. Neutrophil CAPNS1 regulates cardiac inflammation and injury by promoting NETosis in CVB3-induced myocarditis. Free Radic Biol Med. 2026. doi:10.1016/j.freeradbiomed.2026.03.007. PMID: 41786157.
  5. Sideri CK et al. Proteasome Inhibition Amplifies Endoplasmic Reticulum (ER) Stress Responses: Comparative Proteomics of Chinese Hamster Ovary Cell Lines. Biomolecules. 2026. doi:10.3390/biom16020277. PMID: 41750347.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Cytoplasm; Ca²⁺-activated

Frequently Asked Questions

What molecular weight band should I expect for recombinant Calpain-1 on SDS-PAGE or Western blot?

The full-length human Calpain-1 catalytic subunit (CAPN1, 714 aa) runs at approximately 82 kDa under denaturing, reducing SDS-PAGE conditions. Because this recombinant is expressed in HEK293 cells, glycosylation or other post-translational modifications may shift the apparent MW slightly above the predicted 81.7 kDa — a band in the 82–85 kDa range is normal. Autolytic processing, if it occurs, can produce a truncated ~76 kDa species; this is not a degradation artifact but a known feature of activated calpain.

Is this recombinant the full-length Calpain-1 large subunit or a processed / autolytic fragment?

The product is supplied as the full-length 714-amino-acid human CAPN1 catalytic large subunit (UniProt P07384), expressed in HEK293 cells without the regulatory small subunit CAPNS1. It does not arrive pre-complexed as the μ-calpain holoenzyme. Calcium-dependent autolysis at the N-terminal domain I is an intrinsic property of calpain-1; under assay conditions with ≥10 µM Ca²⁺, a minor autolytic fragment (~76 kDa) may appear alongside the intact 82–85 kDa band. For structural studies requiring the intact form, keep Ca²⁺ below activating concentrations during handling.

What substrates does recombinant Calpain-1 cleave and which fluorogenic substrate should I use for activity assays?

Calpain-1 is a cysteine protease (EC 3.4.22.52) with a preference for hydrophobic residues at P2. The most commonly used fluorogenic substrate is Suc-LLVY-AMC (also used for some proteasome assays — confirm with a calpain-specific inhibitor control such as PD150606 or ALLN). Alternatively, t-Boc-LM-CMAC and the cell-permeable substrate Boc-LM-7-amino-4-chloromethylcoumarin work well in vitro. Natural protein substrates include spectrin, talin, and focal adhesion kinase. For a clean kinetic readout, Suc-LLVY-AMC at 50–200 µM in activity buffer provides reliable linear-range fluorescence at Ex/Em 380/460 nm.

What buffer conditions should I use to measure Calpain-1 activity, and how much calcium is needed for activation?

A standard in vitro activity buffer for Calpain-1 is 50 mM HEPES pH 7.4, 100 mM NaCl, 1 mM DTT, with free Ca²⁺ titrated using a CaCl₂/EGTA buffer system. Calpain-1 (μ-calpain) requires micromolar calcium — typically 5–50 µM free Ca²⁺ — for half-maximal activation. Note that the storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) is calcium-free to keep the enzyme quiescent; add calcium only at the time of the assay. DTT or TCEP (0.5–1 mM) is required to maintain the active-site cysteine (Cys115) in the reduced state.

What starting concentration of recombinant Calpain-1 should I use in a fluorogenic substrate activity assay?

For a 96-well plate format using Suc-LLVY-AMC (100 µM substrate), a starting enzyme concentration of 50–200 nM recombinant Calpain-1 in a 100 µL reaction volume typically gives a robust linear signal over 30–60 minutes at 37°C. Titrate down if the signal saturates early; titrate up if activity is below the linear range. Because activity depends on free Ca²⁺, run a Ca²⁺ concentration-response curve (0.1–100 µM) in your first experiment to establish EC₅₀ under your specific buffer conditions. Include a no-enzyme background and a calpastatin or ALLN inhibitor control in every plate.

Can I use recombinant Calpain-1 as a Western blot positive control with the matched TPB anti-Calpain-1 antibody (RP-Calpain1)?

Yes — this is a direct use case for SKU RP-Calpain1 (/anti-calpain-1-rabbit-polyclonal-antibody). The recombinant and the antibody are developed from the same CAPN1 sequence in the same lab, so epitope compatibility is confirmed, not merely predicted. Load 50–100 ng of recombinant Calpain-1 per lane alongside your cell or tissue lysate; a clean band at 82–85 kDa validates that RP-Calpain1 detects the correct molecular weight in your hands. This is particularly useful when running CAPN1 antibody validation experiments or troubleshooting faint endogenous signal in low-expression samples.

How much recombinant Calpain-1 should I load for a Western blot positive control lane?

50–100 ng per lane is sufficient for a strong, clean band when using RP-Calpain1 at its recommended working dilution (typically 1:500–1:2000; confirm on the antibody datasheet). Avoid loading more than 200 ng — excess recombinant can bleed into adjacent sample lanes and complicate quantification. Run the recombinant in a dedicated outer lane, separated from experimental samples by at least one empty lane if your gel format allows. The expected band is 82–85 kDa. If you see a secondary band at ~76 kDa, this is the known autolytic fragment, not a non-specific signal.

How should I store and handle recombinant Calpain-1 to preserve enzymatic activity, and what is its shelf life?

The protein is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — store at -20°C in single-use aliquots. Repeated freeze-thaw cycles progressively reduce activity; plan aliquot volumes around single-experiment use. At -20°C in the supplied buffer, activity is stable for at least 12 months from the date of receipt. On ice during active use, the enzyme is stable for 4–6 hours. Do not dilute into calcium-containing buffers until immediately before the assay to prevent premature autolysis. If you notice loss of activity, verify the reducing agent (DTT or TCEP) in your working buffer is fresh.

Validation imagery coming soon

Western blot validation figures for REC-Calpain1 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →